Koppikar Utpal — SEC insider filings
SEC reporting owner CIK 1742696. 28 insider filings on record with FilingPulse; latest filed 2026-10-20.
Transaction summary — filings shown
Covers all 28 filings on record, filed 2020-08-20 to 2026-10-20. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 5,667 shares, $31,735 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 20 legs across 17 filings — 63,861 shares, $607,285 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 12.
- Largest priced transaction: sale of 5,820 shares @ $14.06 ($81,829) in Atara Biotherapeutics, Inc., filed 2021-06-09.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | Chief Financial Officer | 18 | — | 20 legs · 63,861 sh · $607,285 | 4 |
| C4 Therapeutics, Inc. (CCCC) | Director | 6 | 1 leg · 5,667 sh · $31,735 | — | 5 |
| Flexion Therapeutics Inc (FLXN) | Director | 2 | — | — | 2 |
| INSMED Inc (INSM) | Director | 2 | — | — | 1 |
Insider filings — Koppikar Utpal
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-20 | 3 | INSMED Inc (INSM) | Holdings only — no transactions reported | EDGAR |
| 2026-10-20 | 4 | INSMED Inc (INSM) | Grant/award (A): 6,139 | EDGAR |
| 2026-06-26 | 4 | C4 Therapeutics, Inc. (CCCC) | Grant/award (A): 62,000 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | C4 Therapeutics, Inc. (CCCC) | Grant/award (A): 35,500 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | C4 Therapeutics, Inc. (CCCC) | Grant/award (A): 32,500 (derivative) @ $0 | EDGAR |
| 2023-06-16 | 4 | C4 Therapeutics, Inc. (CCCC) | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2023-03-06 | 4 | Atara Biotherapeutics, Inc. (ATRA) | Sale (S): 6,871 @ $3.63 | EDGAR |
| 2023-02-10 | 4 | C4 Therapeutics, Inc. (CCCC) | Purchase (P): 5,667 @ $5.60 | EDGAR |
| 2023-02-09 | 4 | Atara Biotherapeutics, Inc. (ATRA) | Sale (S): 2,485 @ $5.46 | EDGAR |
| 2022-11-18 | 4 | Atara Biotherapeutics, Inc. (ATRA) | Sale (S): 5,172 @ $4.49 · Sale (S): 1,083 @ $4.49 | EDGAR |
| 2022-08-18 | 4 | Atara Biotherapeutics, Inc. (ATRA) | Sale (S): 5,940 @ $5.04 | EDGAR |
| 2022-06-10 | 4 | Atara Biotherapeutics, Inc. (ATRA) | Sale (S): 5,853 @ $5.63 | EDGAR |
| 2022-05-19 | 4 | Atara Biotherapeutics, Inc. (ATRA) | Sale (S): 4,616 @ $5.32 · Sale (S): 966 @ $5.32 | EDGAR |
| 2022-03-17 | 4 | C4 Therapeutics, Inc. (CCCC) | Grant/award (A): 41,200 (derivative) @ $0 | EDGAR |
| 2022-03-03 | 4 | Atara Biotherapeutics, Inc. (ATRA) | Grant/award (A): 61,235 @ $0 · Sale (S): 2,272 @ $9.86 · Sale (S): 1,491 @ $9.86 · Grant/award (A): 115,107 (derivative) @ $0 | EDGAR |
| 2022-02-09 | 4 | Atara Biotherapeutics, Inc. (ATRA) | Sale (S): 2,496 @ $14.46 | EDGAR |
| 2021-11-19 | 4 | Flexion Therapeutics Inc (FLXN) | Disposition to issuer (D): 32,000 (derivative) | EDGAR |
| 2021-11-18 | 4 | Atara Biotherapeutics, Inc. (ATRA) | Sale (S): 3,655 @ $17.12 | EDGAR |
| 2021-08-19 | 4 | Atara Biotherapeutics, Inc. (ATRA) | Sale (S): 3,579 @ $12.53 | EDGAR |
| 2021-07-12 | 4 | Flexion Therapeutics Inc (FLXN) | Grant/award (A): 32,000 (derivative) @ $0 | EDGAR |
| 2021-06-09 | 4 | Atara Biotherapeutics, Inc. (ATRA) | Sale (S): 5,820 @ $14.06 | EDGAR |
| 2021-05-20 | 4 | Atara Biotherapeutics, Inc. (ATRA) | Sale (S): 3,616 @ $14.55 | EDGAR |
| 2021-03-30 | 4 | Atara Biotherapeutics, Inc. (ATRA) | Sale (S): 1,761 @ $14.58 | EDGAR |
| 2021-03-04 | 4 | Atara Biotherapeutics, Inc. (ATRA) | Sale (S): 1,461 @ $16.74 | EDGAR |
| 2021-03-03 | 4 | Atara Biotherapeutics, Inc. (ATRA) | Grant/award (A): 45,258 @ $0 · Grant/award (A): 68,314 (derivative) @ $0 | EDGAR |
| 2021-02-09 | 4 | Atara Biotherapeutics, Inc. (ATRA) | Sale (S): 1,759 @ $20.39 | EDGAR |
| 2020-11-18 | 4 | Atara Biotherapeutics, Inc. (ATRA) | Sale (S): 1,469 @ $19.77 | EDGAR |
| 2020-08-20 | 4 | Atara Biotherapeutics, Inc. (ATRA) | Sale (S): 1,496 @ $12.09 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-08-18 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1742696 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs